<![CDATA[Weighing the Catabolic Effects of Lenvatinib/Everolimus vs SOC in ccRCC]]>

Data ReadoutLenvatinib/EverolimusCabozantinibNeutral

AI Analysis

Summary

Dr. María Teresa Bourlon discussed data comparing body composition and muscle loss effects of lenvatinib/everolimus versus cabozantinib in metastatic clear cell renal cell carcinoma treatment.

Clinical Trial Data

Outcome Details

Body composition and muscle loss data comparing lenvatinib/everolimus vs cabozantinib in metastatic ccRCC

Importance:3/10

Sentiment:

0.00

oncologyrenal cell carcinomalenvatinibeverolimuscabozantinibbody compositioncatabolic effects

Related Companies

$ESALY $NVS

Read the original article

Published by Cancer Network on July 29, 2026 6:00 PM

Read Original